Form 4: Theravance Biopharma Executive Granted 100,000 RSUs with Performance-Based Vesting

Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., was granted 100,000 Restricted Stock Units (RSUs) on April 2, 2024, with vesting conditions based on service and share price appreciation.

Summary

• On April 2, 2024, Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc., received a grant of 100,000 Restricted Stock Units (RSUs).
• 37,500 of these RSUs are subject to service-based vesting conditions.
• The remaining 62,500 RSUs vest based on the achievement of share price appreciation targets and continued employment.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of an RSU grant. It's neutral to slightly positive as it incentivizes management.

Positives

• The grant of RSUs to a key executive aligns their interests with those of the shareholders, incentivizing them to drive share price appreciation.

Risks

• The vesting of a significant portion of the RSUs is contingent on achieving share price appreciation targets, which may not be met.

Future Outlook

The vesting of the RSUs is dependent on future service and the achievement of share price appreciation targets.

Industry Context

Grants of RSUs are a common form of executive compensation in the biopharmaceutical industry, aligning executive incentives with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages in the biopharmaceutical industry typically include a mix of base salary, bonus, stock options, and restricted stock units.
• The specific terms of RSU grants, such as vesting schedules and performance targets, vary widely depending on the company's size, stage of development, and strategic goals.
• Comparing Theravance Biopharma's executive compensation practices to those of its peers (e.g., other publicly traded biopharmaceutical companies with similar market capitalizations and product pipelines) would provide a more comprehensive assessment of its competitiveness.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with share price appreciation.
• The executive receiving the grant benefits from the potential for increased compensation if the company performs well.

Key Dates